You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Paris Pearls: Key Updates Surrounding the Use of Immunotherapy for Advanced NSCLC

  • Authors: Hossein Borghaei, DO, MS; Mark A. Socinski, MD; Melina E. Marmarelis, MD, MSCE
  • CME / ABIM MOC Released: 9/28/2022
  • Valid for credit through: 9/28/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pathologists, pulmonologists, and other clinicians on the NSCLC multidisciplinary care team (MDT).

The goal of this activity is that learners will be better able to improve clinicians' understanding of the latest data evaluating immunotherapy-containing regimens for the treatment of patients with advanced NSCLC and how best to incorporate these data into the clinical management of affected patients.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Recent clinical trial data evaluating immunotherapy-containing treatment strategies for patients with advanced NSCLC
  • Have greater competence related to
    • Selecting the most appropriate immunotherapy-containing treatment regimen for a patient with advanced NSCLC
  • Demonstrate greater confidence in their ability to
    • Incorporate recent immunotherapy clinical trial data into the care of patients with advanced NSCLC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Hossein Borghaei, DO, MS

    Chief, Division of Thoracic Medical Oncology
    Professor, Department of Hematology/Oncology
    Co-Director, Immune Monitoring Facility
    Gloria and Edmund M. Dunn Chair in Thoracic Oncology
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Disclosures

    Hossein Borghaei, DO, MS, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; AstraZeneca; Axiom; Beigene; BioNTech; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Da Volterra; EMD Serono; Genentech; Genmab; Guardant; iTEO; Janssen; Jazz; Lilly; Merck; Mirati; Natera; Novartis; Oncocyte; Pfizer; PharmaMar; Regeneron; Takeda
    Research funding from: Amgen; Bristol Myers Squibb; Lilly
    Stock options from: Inspirna, formerly Rgenix; Nucleai; Sonnet Bio
    Other: Data and Safety Monitoring Board: University of Pennsylvania, CAR T Program; Incyte Corporation; Novartis; Takeda 

  • Mark A. Socinski, MD

    Executive Medical Director
    AdventHealth Cancer Institute
    Orlando, Florida

    Disclosures

    Mark A. Socinski, MD, has the following relevant financial relationships:
    Consultant or advisor for: Beigene; Genentech; Lilly
    Speaker or member of speakers bureau for: Amgen; Astra Zeneca; Bristol Myers Squibb; G1Therapeutics; Genentech; Guardant; Janssen; Jazz; Lilly; Merck; Regeneron; Sanofi; Takeda
    Research funding from: Cullinan; Genentech; Novartis; Spectrum; Takeda

  • Melina E. Marmarelis, MD, MSCE

    Assistant Professor
    University of Pennsylvania
    Medical Director
    Penn Medicine Mesothelioma and Pleural Disease Program
    Philadelphia, Pennsylvania

    Disclosures

    Melina E. Marmarelis, MD, MSCE, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Blueprint Pharmaceuticals; Boehringer Ingelheim; Bristol Myers Squibb; Ikena; Janssen; Novocure; Takeda
    Research funding from: AstraZeneca; Eli Lilly; Merck; Trizell
    Contracted researcher for: AstraZeneca; Blueprint Pharmaceuticals; Boehringer Ingelheim; Bristol Myers Squibb; Ikena; Janssen; Novocure; Takeda
    Stock options from: Bluebird Biosciences; Gilead; Janssen; Merck; Novartis; Pfizer; Portola Pharmaceuticals

Editor

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC

    Disclosures

    Amy Furedy, RN, OCN, has no relevant financial relationships.

  • Charlotte Warren

    Senior Director, Content Development, Medscape, LLC

    Disclosures

    Charlotte Warren has no relevant financial relationships.

  • Andrew D. Bowser, ELS, CHCP

    Scientific Content Manager, Medscape, LLC

    Disclosures

    Andrew D. Bowser, ELS, CHCP, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Paris Pearls: Key Updates Surrounding the Use of Immunotherapy for Advanced NSCLC

Authors: Hossein Borghaei, DO, MS; Mark A. Socinski, MD; Melina E. Marmarelis, MD, MSCEFaculty and Disclosures

CME / ABIM MOC Released: 9/28/2022

Valid for credit through: 9/28/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Dual Checkpoint Inhibition in NSCLC

What is the role of dual checkpoint inhibition, either with or without chemotherapy, in NSCLC?
Hossein Borghaei, DO, MS

Immunotherapy With and Without Chemotherapy in NSCLC

Who are candidates for single agent immunotherapy -- and when should it be combined with chemotherapy in NSCLC?
Mark A. Socinski, MD

Second-Line Immunotherapy Approaches in NSCLC

What is the optimal use of immunotherapy in the second line for treating NSCLC?
Melina E. Marmarelis, MD, MSCE
 

Learning Feedback Questions

Please answer these questions to complement your learning experience.